drugset / Trial / NCT07260175

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

NCT07260175

NaSingle-groupOpen-labelTreatment

Summary

This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Timeline

Start
2025-11-18
Primary completion
2030-12
Completion
2031-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivosidenib Small molecule 500 mg

Indications